Compare

Vericel/$VCEL

1D1W1M3M6MYTD1Y5YMAX

About Vericel

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Ticker
$VCEL
Sector
Health
Primary listing
NASDAQ
Employees
398

Vericel Metrics

BasicAdvanced
$2.9B
93.25
$0.62
1.06
-

What the Analysts think about Vericel

Analyst ratings (Buy, Hold, Sell) for Vericel stock.
Analyst projections of the future price of Vericel stock.

Bulls say / Bears say

MACI remains a strong growth engine: third-quarter sales rose 21%, its sixth straight quarter of growth above 20%, with record biopsies and implants. Vericel raised its full-year MACI revenue outlook to $290–292 million. (GlobeNewswire)
The burn-care franchise is growing quickly too: revenue rose 52% to a record $18 million, while commercial NexoBrid sales increased 54% and Epicel sales rose 23%. Repeat orders from about 70 of the more than 80 centres that have ordered NexoBrid point to wider use. (GlobeNewswire, The Motley Fool)
Profitability and cash generation are improving: third-quarter net income rose 179%, adjusted EBITDA margin reached 30%, and free cash flow was $15.7 million. Vericel raised its full-year adjusted EBITDA margin outlook to 28% and ended the quarter with $235.6 million in cash and investments and no debt. (GlobeNewswire)
Revenue is concentrated in MACI: it generated about 79% of third-quarter sales. A slowdown in surgeon adoption or pressure on reimbursement could therefore weigh heavily on results. (GlobeNewswire, SEC)
Burn-care demand can be difficult to forecast: management said it cannot control how many catastrophic burns occur or how many patients survive to be treated. That makes Epicel sales, and quarterly results, less predictable. (The Motley Fool)
Manufacturing and supply disruptions could limit growth: Vericel is transitioning MACI production to its Burlington facility and warns that scaling its own manufacturing or securing NexoBrid supplies from MediWound could be difficult. The company also flags potential disruption to supply and shipping routes in the Middle East. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.

Vericel Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Vericel Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing Vericel

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.